Marginal pulmonary function should not preclude lobectomy in selected patients with non-small cell lung cancer
- PMID: 24252944
- DOI: 10.1016/j.jtcvs.2013.09.064
Marginal pulmonary function should not preclude lobectomy in selected patients with non-small cell lung cancer
Abstract
Objective: Current clinical trials are investigating the role of stereotactic body radiation therapy (SBRT) versus sublobar resection for patients with non-small cell lung carcinoma (NSCLC) and marginal pulmonary function tests (M-PFTs). We compared the outcomes of patients undergoing lobectomy with M-PFTs characterized by 2 accepted M-PFT criteria.
Methods: A total of 1,259 consecutive patients underwent lobectomy for NSCLC between 1999 and 2011. Patients were stratified into 2 classifications of M-PFT: American College of Surgeons Oncology Group (ACOSOG) Z4099/Radiation Therapy Oncology Group (RTOG) 1021 trial or American College of Chest Physicians (ACCP) criteria. There were 206 patients classified as having M-PFT according to ACOSOG Z4099/RTOG 1021 criteria and 131 patients classified as having M-PFT by ACCP criteria. The primary endpoints of the study were post-operative complications and survival.
Results: Median follow-up was 3.8 years. Cox-proportional survival analysis found that pathologic stage (P < .001), age (P < .001), and higher Zubrod functional status (P < .001) were independent predictors of mortality. Using multivariable analysis for major morbidity, M-PFT status was not associated with the development of a major complication following lobectomy (P = .68). M-PFT classification was not an independent predictor of mortality when controlling for other variables (ACOSOG Z4099/RTOG 1021 [P = .34]; ACCP criteria [P = .83]). A composite major morbidity analysis for major morbidity following lobectomy showed no association between clinicopathologic variables or M-PFTs and the occurrence of a major postoperative morbidity.
Conclusions: In carefully selected patients with M-PFTs, lobectomy for NSCLC can be performed with acceptable morbidity and mortality. These results need to be considered when deciding if a patient should undergo lobectomy or other therapies for resectable NSCLC.
Keywords: 10; ACCP; ACSOG; American College of Chest Physicians; American College of Surgeons Oncology Group; CT; DLCO; FEV1; M-PFT; NSCLC; RFA; RTOG; Radiation Therapy Oncology Group; SBRT; STS; The Society of Thoracic Surgeons; computed tomography; diffusing capacity for carbon monoxide; forced expiratory volume in 1 second; marginal pulmonary function test; non–small cell lung carcinoma; radiofrequency ablation; stereotactic body radiotherapy.
Copyright © 2014 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.
Similar articles
-
Treatment of stage I lung cancer in high-risk and inoperable patients: comparison of prospective clinical trials using stereotactic body radiotherapy (RTOG 0236), sublobar resection (ACOSOG Z4032), and radiofrequency ablation (ACOSOG Z4033).J Thorac Cardiovasc Surg. 2013 Mar;145(3):692-9. doi: 10.1016/j.jtcvs.2012.10.038. Epub 2012 Nov 20. J Thorac Cardiovasc Surg. 2013. PMID: 23174176
-
Development of a patient-centered aggregate score to predict survival after lung resection for non-small cell lung cancer.J Thorac Cardiovasc Surg. 2013 Aug;146(2):385-90.e1-2. doi: 10.1016/j.jtcvs.2013.04.007. Epub 2013 May 4. J Thorac Cardiovasc Surg. 2013. PMID: 23651911
-
Risk factor analysis of locoregional recurrence after sublobar resection in patients with clinical stage IA non-small cell lung cancer.J Thorac Cardiovasc Surg. 2013 Aug;146(2):372-8. doi: 10.1016/j.jtcvs.2013.02.057. J Thorac Cardiovasc Surg. 2013. PMID: 23870323
-
Segmental resection spares pulmonary function in patients with stage I lung cancer.Ann Thorac Surg. 2004 Jul;78(1):228-33; discussion 228-33. doi: 10.1016/j.athoracsur.2004.01.024. Ann Thorac Surg. 2004. PMID: 15223434 Review.
-
In elderly patients with lung cancer is resection justified in terms of morbidity, mortality and residual quality of life?Interact Cardiovasc Thorac Surg. 2010 Jun;10(6):1015-21. doi: 10.1510/icvts.2010.233189. Epub 2010 Mar 30. Interact Cardiovasc Thorac Surg. 2010. PMID: 20354037 Review.
Cited by
-
Administrative and clinical databases: General thoracic surgery perspective on approaches and pitfalls.J Thorac Cardiovasc Surg. 2021 Oct;162(4):1146-1153. doi: 10.1016/j.jtcvs.2021.03.057. Epub 2021 Mar 19. J Thorac Cardiovasc Surg. 2021. PMID: 33892944 Free PMC article.
-
Robotic lobectomy has the greatest benefit in patients with marginal pulmonary function.J Cardiothorac Surg. 2018 Jun 5;13(1):56. doi: 10.1186/s13019-018-0748-z. J Cardiothorac Surg. 2018. PMID: 29871643 Free PMC article.
-
[Multidisciplinary team model for patients with oral cancer and systemic diseases: an expert consensus].Hua Xi Kou Qiang Yi Xue Za Zhi. 2020 Dec 1;38(6):603-615. doi: 10.7518/hxkq.2020.06.001. Hua Xi Kou Qiang Yi Xue Za Zhi. 2020. PMID: 33377335 Free PMC article. Chinese.
-
Prognostic Impact of Postoperative Complications in High-Risk Operable Non-small Cell Lung Cancer.J Chest Surg. 2022 Feb 5;55(1):20-29. doi: 10.5090/jcs.21.100. J Chest Surg. 2022. PMID: 35115418 Free PMC article.
-
Lobectomy for patients with marginal pulmonary function: an indication for robotics.J Thorac Dis. 2019 Jun;11(6):E86-E87. doi: 10.21037/jtd.2019.05.65. J Thorac Dis. 2019. PMID: 31372303 Free PMC article. No abstract available.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical